18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer

被引:18
|
作者
Salem, Kelley [1 ]
Kumar, Manoj [1 ]
Powers, Ginny L. [1 ,5 ]
Jeffery, Justin J. [2 ]
Yan, Yongjun [1 ,3 ]
Mahajan, Aparna M. [4 ]
Fowler, Amy M. [1 ,2 ,3 ]
机构
[1] Univ Wisconsin, Sch Med & Publ Hlth, Dept Radiol, 600 Highland Ave, Madison, WI 53792 USA
[2] Univ Wisconsin, Sch Med & Publ Hlth, Carbone Canc Ctr, 600 Highland Ave, Madison, WI 53792 USA
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med Phys, 600 Highland Ave, Madison, WI 53792 USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, 600 Highland Ave, Madison, WI 53792 USA
[5] Kendrick Labs, Madison, WI USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; PROTEASOME-MEDIATED PROTEOLYSIS; SMALL-ANIMAL PET; IN-VIVO; TARGET TISSUES; ESR1; MUTATIONS; F-18-FLUOROESTRADIOL; THERAPY; RESPONSIVENESS; FEASIBILITY;
D O I
10.1148/radiol.2017162956
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To determine the binding specificity of F-18-16 alpha-17 beta-fluoroestradiol (FES) in estrogen receptor (ER) alpha-positive breast cancer cells and tumor xenografts. Materials and Methods: Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ER alpha (231 G521R ER), which is defective in estradiol binding. ERa protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results: ERa transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ ID] per gram, 0.49 +/- 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 +/- 0.051; P =.20) and nonspecific muscle uptake (percent ID per gram, 0.41 +/- 0.0095; P =.06). Conclusion: This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERa with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. (C) RSNA, 2017
引用
收藏
页码:868 / 876
页数:9
相关论文
共 50 条
  • [21] Geographic excess of estrogen receptor-positive breast cancer
    Benz, CC
    Clarke, CA
    Moore, DH
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (12) : 1523 - 1527
  • [22] Estrogen receptor-positive breast cancer: a multidisciplinary challenge
    Zwart, Wilbert
    Theodorou, Vasiliki
    Carroll, Jason S.
    WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE, 2011, 3 (02) : 216 - 230
  • [23] Risk factors for estrogen receptor-positive breast cancer
    Hwang, ES
    Chew, T
    Shiboski, S
    Farren, G
    Benz, CC
    Wrensch, M
    ARCHIVES OF SURGERY, 2005, 140 (01) : 58 - 62
  • [24] Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer
    Zhang, Xiang H. -F.
    Giuliano, Mario
    Trivedi, Meghana V.
    Schiff, Rachel
    Osborne, C. Kent
    CLINICAL CANCER RESEARCH, 2013, 19 (23) : 6389 - 6397
  • [25] [18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases
    Ivanidze, Jana
    Sharbatdaran, Arman
    McCalla, Aliah
    Brandmaier, Andrew
    Andreopoulou, Eleni
    Cristofanilli, Massimo
    Cigler, Tessa
    Balogun, Onyinye D.
    Magge, Rajiv S.
    Liechty, Benjamin
    Karakatsanis, Nicolas A.
    Nehmeh, Sadek A.
    Agee, Matthew A.
    Jean, Jolie
    Osborne, Joseph R.
    Beal, Kathryn
    Schwartz, Theodore H.
    Pannullo, Susan C.
    Knisely, Jonathan P. S.
    Ramakrishna, Rohan
    EUROPEAN JOURNAL OF RADIOLOGY, 2024, 181
  • [26] Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[18F]fluoroestradiol ([18F]FES)for human breast cancer imaging
    Wang, Min
    Glick-Wilson, Barbara E.
    Zheng, Qi-Huang
    APPLIED RADIATION AND ISOTOPES, 2020, 160 (160)
  • [27] Automated production of 16α-[18F]fluoroestradiol for breast cancer imaging
    Römer, J
    Füchtner, F
    Steinbach, J
    Johanssen, B
    NUCLEAR MEDICINE AND BIOLOGY, 1999, 26 (04) : 473 - 479
  • [28] 16a-18F-fluoro-17b-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer
    Ulaner, Gary A.
    SEMINARS IN NUCLEAR MEDICINE, 2022, 52 (05) : 574 - 583
  • [29] Progesterone receptor signaling in estrogen receptor-positive breast cancer.
    Young, Amy
    Guan, Jane
    Daemen, Anneleen
    Friedman, Lori
    Lin, Kui
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 81 - 81
  • [30] The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer
    Hickey, Theresa E.
    Selth, Luke A.
    Chia, Kee Ming
    Laven-Law, Geraldine
    Milioli, Heloisa H.
    Roden, Daniel
    Jindal, Shalini
    Hui, Mun
    Finlay-Schultz, Jessica
    Ebrahimie, Esmaeil
    Birrell, Stephen N.
    Stelloo, Suzan
    Iggo, Richard
    Alexandrou, Sarah
    Caldon, C. Elizabeth
    Abdel-Fatah, Tarek M.
    Ellis, Ian O.
    Zwart, Wilbert
    Palmieri, Carlo
    Sartorius, Carol A.
    Swarbrick, Alex
    Lim, Elgene
    Carroll, Jason S.
    Tilley, Wayne D.
    NATURE MEDICINE, 2021, 27 (02) : 310 - +